This report presents the results of the first external quality assurance (EQA) scheme for B. pertussis antimicrobial susceptibility testing by ECDC as part of the European Reference Laboratory Network for Pertussis (ERLNPert-Net) consortium.
This report presents the results of the first external quality assessment (EQA) scheme for Bordetella pertussis vaccine antigen expression, pertactin (PRN), pertussis toxin (PT) and filamentous haemagglutinin (FHA) by the European Centre for Disease Prevention and Control (ECDC) as part of the European Reference Laboratory Network for Pertussis (ERLNPert-Net) activities.
This literature review, covering the period from 2000 to January 2022, assessed the state of knowledge on biocide resistance in wild vector populations across the EU/EEA and neighbouring countries.
The overall aim of the protocol is to support the implementation of a PPS of HAIs and antimicrobial use in European long-term care facilities, to meet the abovementioned objectives for ECDC surveillance.
This evidence brief summarises key issues and priorities for action in Europe and Central Asia on PrEP. It is largely based on data collected between February and August 2022.
In 2016–2017, the European Centre for Disease Prevention and Control (ECDC) organised the third point prevalence survey (PPS) of healthcare-associated infections (HAIs) and antimicrobial use in European long-term care facilities (LTCFs) or HALT-3.
This guidance document includes an updated summary of diagnostic PCR and serology together with detailed information on isolation, culture, identification and epidemiological typing of B. pertussis to help users choose the best methods within the local technical and financial provisions.